LivaNova PLC $LIVN Holdings Reduced by Redmile Group LLC

Redmile Group LLC lessened its stake in LivaNova PLC (NASDAQ:LIVN) by 7.9% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 934,271 shares of the company’s stock after selling 79,868 shares during the quarter. LivaNova accounts for about 4.5% of Redmile Group LLC’s portfolio, making the stock its 8th largest holding. Redmile Group LLC owned about 1.71% of LivaNova worth $42,061,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its position in shares of LivaNova by 182.5% in the second quarter. GAMMA Investing LLC now owns 630 shares of the company’s stock worth $28,000 after acquiring an additional 407 shares during the period. EverSource Wealth Advisors LLC grew its holdings in LivaNova by 998.4% in the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after purchasing an additional 639 shares during the period. Parallel Advisors LLC increased its position in shares of LivaNova by 1,312.3% in the second quarter. Parallel Advisors LLC now owns 1,031 shares of the company’s stock valued at $46,000 after buying an additional 958 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its stake in shares of LivaNova by 415.4% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,469 shares of the company’s stock worth $58,000 after buying an additional 1,184 shares during the period. Finally, Strs Ohio purchased a new position in shares of LivaNova during the 1st quarter valued at approximately $130,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Stock Performance

NASDAQ LIVN opened at $63.95 on Friday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.12 and a current ratio of 1.33. The stock’s fifty day moving average is $56.06 and its two-hundred day moving average is $51.39. The firm has a market capitalization of $3.49 billion, a P/E ratio of -15.99 and a beta of 1.02. LivaNova PLC has a fifty-two week low of $32.48 and a fifty-two week high of $65.57.

Analyst Ratings Changes

A number of research firms have weighed in on LIVN. Barclays upped their price objective on shares of LivaNova from $55.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 21st. Needham & Company LLC restated a “buy” rating and set a $64.00 price target on shares of LivaNova in a research report on Wednesday, September 3rd. Robert W. Baird lifted their price objective on LivaNova from $63.00 to $70.00 and gave the stock an “outperform” rating in a report on Thursday, November 13th. Weiss Ratings reiterated a “sell (d+)” rating on shares of LivaNova in a research note on Monday. Finally, Wall Street Zen downgraded LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 6th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, LivaNova has a consensus rating of “Moderate Buy” and a consensus price target of $62.43.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.